JPWO2019179424A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019179424A5
JPWO2019179424A5 JP2020550641A JP2020550641A JPWO2019179424A5 JP WO2019179424 A5 JPWO2019179424 A5 JP WO2019179424A5 JP 2020550641 A JP2020550641 A JP 2020550641A JP 2020550641 A JP2020550641 A JP 2020550641A JP WO2019179424 A5 JPWO2019179424 A5 JP WO2019179424A5
Authority
JP
Japan
Prior art keywords
seq
antibody
glp
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518132A (ja
JP7313372B2 (ja
JP2021518132A5 (https=
Publication date
Priority claimed from CN201810231468.XA external-priority patent/CN110305211A/zh
Application filed filed Critical
Publication of JP2021518132A publication Critical patent/JP2021518132A/ja
Publication of JPWO2019179424A5 publication Critical patent/JPWO2019179424A5/ja
Publication of JP2021518132A5 publication Critical patent/JP2021518132A5/ja
Application granted granted Critical
Publication of JP7313372B2 publication Critical patent/JP7313372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550641A 2018-03-20 2019-03-19 Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 Active JP7313372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810231468.XA CN110305211A (zh) 2018-03-20 2018-03-20 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN201810231468.X 2018-03-20
PCT/CN2019/078671 WO2019179424A1 (zh) 2018-03-20 2019-03-19 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用

Publications (4)

Publication Number Publication Date
JP2021518132A JP2021518132A (ja) 2021-08-02
JPWO2019179424A5 true JPWO2019179424A5 (https=) 2022-04-18
JP2021518132A5 JP2021518132A5 (https=) 2022-04-18
JP7313372B2 JP7313372B2 (ja) 2023-07-24

Family

ID=67986692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550641A Active JP7313372B2 (ja) 2018-03-20 2019-03-19 Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途

Country Status (10)

Country Link
US (1) US11780916B2 (https=)
EP (1) EP3808771A4 (https=)
JP (1) JP7313372B2 (https=)
KR (1) KR20200133365A (https=)
CN (3) CN117003874A (https=)
AU (1) AU2019236822B2 (https=)
BR (1) BR112020019052A2 (https=)
CA (1) CA3094286A1 (https=)
TW (1) TWI832847B (https=)
WO (1) WO2019179424A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
EP4352104A4 (en) * 2021-06-09 2025-06-04 Swiftnovo Therapeutics Inc. Therapeutics and methods for treating or ameliorating metabolic disorders
JP2025531814A (ja) * 2022-09-08 2025-09-25 ジーマックス バイオファーム エルエルシー Gipr抗体、fgf21との融合タンパク質、その医薬組成物及びその使用
EP4613768A1 (en) * 2022-11-02 2025-09-10 Suzhou Alphamab Co., Ltd Gipr binding protein and use thereof
WO2025237353A1 (zh) * 2024-05-15 2025-11-20 信立泰(成都)生物技术有限公司 一种抗gipr抗体或其抗原结合片段及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EP2411412B1 (en) * 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against light and uses thereof
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
AR104250A1 (es) 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
KR102844773B1 (ko) * 2015-12-23 2025-08-13 암젠 인크 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
MX2019015544A (es) * 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).

Similar Documents

Publication Publication Date Title
CN107206077B (zh) 靶向g-蛋白偶联受体的抗体和使用方法
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
JP6669722B2 (ja) Cd3結合ドメイン
RU2016108703A (ru) Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок
JP2020508655A5 (https=)
JP2019520797A5 (https=)
JP2021518132A5 (https=)
JP2020536532A5 (https=)
JP2018522888A5 (https=)
JP2005518789A5 (https=)
JP2013515508A5 (https=)
JP2020524661A5 (https=)
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
JPWO2022111425A5 (https=)
JP2021518748A5 (https=)
JPWO2019175368A5 (https=)
JPWO2019179424A5 (https=)
JPWO2021052349A5 (https=)
JP2026500703A (ja) 融合タンパク質
JP2021526833A5 (https=)
JPWO2022150788A5 (https=)
JPWO2019165326A5 (https=)
JPWO2022212470A5 (https=)
JPWO2019238093A5 (https=)
RU2020130794A (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение